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Resonance Imaging for Detection of Arteritic Anterior Ischemic
Optic Neuropathy in Patients With Giant Cell Arteritis
Nora N. Sommer, MD,* Karla M. Treitl, MD,*† Eva Coppenrath, MD,* Hendrik Kooijman, PhD,‡
Claudia Dechant, MD,§ Michael Czihal, MD,|| Theresa M. Kolben, MD,¶ Sebastian E. Beyer, MD,*
Wieland H. Sommer, MD,* and Tobias Saam, MD*#Objectives:Arteritic anterior ischemic optic neuropathy (A-AION) caused by in-
flammatory occlusion of the posterior ciliary arteries is the most common reason
for irreversible vision loss in patients with giant cell arteritis. Atypical clinical
presentation and negative funduscopy can delay systemic high-dose corticoste-
roid therapy to prevent impending permanent blindness and involvement of the
contralateral eye.
The purpose of this study was to assess the diagnostic accuracy of 3-dimensional
(3D) high-resolution T1-weighted black-blood magnetic resonance imaging
(T1-BB-MRI) for the detection of posterior ciliary artery involvement in pa-
tients with giant cell arteritis and funduscopic A-AION.
Materials andMethods:After institutional review board approval and informed
consent, 27 patients with suspected giant cell arteritis and vision disturbances
were included in this monocentric prospective cohort study. Giant cell arteritis
was diagnosed in 18 patients according to the diagnostic reference standard
(6 men, 73.8 [69.0–78.0] years); 14 of thosewere positive for A-AION. Precontrast
and postcontrast 3D T1-BB-MRIwas performed in all 27 patients. Two radiologists
separately assessed image quality and local fat suppression (4-point scale), visual
contrast enhancement (3-point scale), and diagnostic confidence (5-point scale)
regarding arteritic posterior ciliary artery involvement. Magnetic resonance
imaging findings were assessed in comparison to funduscopy. Statistical analysis
included accuracy parameters and interrater agreement.
Results: Sensitivity of 3D T1-BB-MRI was 92.9% (95% confidence interval,
66.1%–99.8%) and specificity was 92.3% (95% confidence interval, 64.0%–
99.8%) for detection of A-AION–positive patients. Image quality and local fat
suppression were assessed with 3.2 ± 0.8 (median 3) and 3.8 ± 0.5 (median 4).
Visual contrast enhancement with 2.3 ± 0.8 (median 3) and diagnostic confidence
was rated at 4.7 ± 0.5 (median 5). Interrater agreement was high (κ = 0.85,
P < 0.001). Three-dimensional T1-BB-MRI displayed bilateral findings in 50%
of the cases, whereas only unilateral A-AION was detected in funduscopy as a
possible indication for the contralateral eye at risk.
Conclusions: Three-dimensional T1-BB-MRI allows accurate detection of
arteritic posterior ciliary artery involvement in patients with A-AION. Further,
3D T1-BB-MRI seems to display arteritic involvement of the posterior ciliary
arteries earlier than funduscopy and might, therefore, display “vision-at-risk”Received for publication March 28, 2018; and accepted for publication, after revision,
May 8, 2018.
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V ision loss occurs in approximately 20% of patients with giant cellarteritis (GCA)1,2 and is considered to be an ophthalmologic emer-
gency requiring immediate diagnosis and early initiation of intravenous
high-dose corticosteroid therapy to prevent impending permanent
blindness and involvement of the contralateral eye.3–5
Arteritic anterior ischemic optic neuropathy (A-AION) is the
most common reason for permanent vision impairment in patients with
GCA.2,4,6 Arteritic anterior ischemic optic neuropathy is caused by
arteritic ischemia of the anterior part of the optic nerve secondary to in-
flammatory occlusion of the posterior ciliary arteries.6–8 In the clinical
context of GCA, a pale edematous optic nerve head is considered to be
the funduscopic correlate of A-AION.7–9
However, diagnosing GCAandA-AIONmay be challenging: al-
though the American College of Rheumatology has established criteria
for the classification of GCA,10 validated diagnostic criteria are not
available. Moreover, atypical clinical presentation of GCA is not un-
usual, with patients presenting with a normal erythrocyte sedimentation
rate (ESR),11–13 or false-negative results of temporal artery biopsy
(TAB) due to skip lesions.14–16 In addition, up to 21% of patients with
biopsy-proven GCA present with isolated A-AION without systemic
symptoms.17 Furthermore, arteritic posterior ischemic optic neuropathy
(A-PION), a condition of ischemic occlusion of the pial vascular plexus
supplied by collateral branches of the central retinal artery and the oph-
thalmic artery, is a rare cause of GCA-related blindness; however, it
causes diagnostic difficulties, because no morphologic correlate can
be seen in funduscopy.7–9 There are some promising results using
diffusion-weighted imaging for detection of A-PION18,19; however,
larger studies are needed to confirm this initial results.
Therefore, new diagnostic pathways should be explored. Black-
blood magnetic resonance imaging (MRI) enables visualization of
arteritic changes of vessels displaying circumferential thickening and
strong contrast enhancement of the vessel wall.20–23 Until lately, con-
ventional black-blood MRI based on double-inversion recovery tech-
niques was restricted due to 2-dimensional (2D) acquisition mode,
low spatial resolution, small coverage, and time concerns.20,24,25 We
recently developed a 3-dimensional (3D) T1-weighted (T1) black-
blood (BB) turbo spin echo (TSE) sequence with variable flip-angle
refocusing pulses and submillimeter isotropic resolution (3D T1-BB-
MRI), allowing imaging of small vessels and image-reconstruction in
all 3 planes. Three-dimensional T1-BB-MRI has been already proved
to detect thoracic large vessel vasculitis26 and deep vein thrombosis.27estigative Radiology • Volume 53, Number 11, November 2018
ealth, Inc. All rights reserved.
TABLE 1. Parameters of 3D T1-BB-MRI
3D T1-mVISTA




SENSE factor (AP)/(RL) 1.7/2.5
Echo spacing/ETL 4.4/268
Echo pulse angle, degree Variable; minimum, 50 degrees;
maximum 120 degrees
NSA 2
Scan FOV, mm3 200  251  160
Recon matrix 640
No. slices 427
Voxel size, mm3 0.75  0.75  0.75
Recon voxel size, mm3 0.39  0.39  0.35
Scan time, min 4:43
Flow compensation No
Slice orientation Sagittal
3D indicates 3-dimensional; T1-BB-MRI, T1-weighted black-blood magnetic
resonance imaging; AP, anterior-posterior; ETL, echo train length; FOV, field of
view; NSA, number of signal averages; RL, right-left; SENSE, parallel acquisition
technique; SPIR, spectral presaturation with inversion recovery; T1, T1-weighted;
TE, echo time; TR, repetition time; TSE, turbo spin echo; T1-mVISTA, T1-
weighted modified volumetric isotropic TSE acquisition.
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of 3D T1-BB-MRI for the detection of posterior ciliary artery involve-
ment in patients with GCA and funduscopic A-AION.
MATERIALS AND METHODS
Study Design and Study Population
The study was designed as a prospective monocentric co-
hort study. Institutional review board approval was given and writ-
ten informed consent obtained from all patients before image
acquisition. The study protocol followed the principles of the
Declaration of Helsinki. All imaging procedures were performed
for clinical reasons. Patients were recruited between September
2013 and April 2017.
Inclusion Criteria
Patients 50 years and older with visual symptoms (including am-
aurosis fugax, diplopia, rapid visual loss, blindness) and their first epi-
sode of suspected GCAwere included in the study. After admission, all
patients received (1) a complete MRI protocol (mentioned below) and
(2) a funduscopy of both eyes.
Diagnostic Reference Standard for the Diagnosis
of GCA
A definitive diagnosis or exclusion of GCAwas determined for
each patient according the diagnostic reference standard described sub-
sequently: all patients suspected of GCA underwent laboratory testing
(blood count, c-reactive protein, ESR) and a standardized color duplex
sonography (CDS) of the superficial temporal arteries. A sonographer
with more than 8 years of experience performed CDS using a GE
LOGIC E9 ultrasound unit (GE Healthcare, Munich, Germany) with
a 5- to 16-MHz broadband linear transducer. A hypoechogenic circum-
ferential wall thickening (halo) in any segment of the temporal arteries
was considered a positive CDS finding for GCA.28,29 The diagnosis of
GCAwas finally established in an interdisciplinary consensus decision
by experienced rheumatologists and angiologists by fulfillment of at
least 3 of the American College of Rheumatology classification criteria
for cranial GCA,10 in the presence of the typical CDS findings men-
tioned previously or by a positive TAB, together with typical clinical
signs of GCA.
Funduscopic Examination
All patients underwent an ophthalmologic council including fun-
duscopy. Funduscopic findings were reviewed by experienced ophthal-
mologists to diagnose or exclude A-AION according to the following
criteria: if funduscopy revealed a pale edematous optic disc, A-AION
was considered to be the cause, whereas a hyperemic edema of the
optic disc and a small cup with a crowded optic disc contralaterally
were referred to be a cause of a nonarteritic atherosclerotic AION
(NA-AION).6–8,30
Exclusion Criteria
Patients were excluded when one of the following criteria was
present: (1) definitive diagnosis or exclusion of GCAwas not possible
based on the reference standard; (2) GCA suspected, but patients had
corticosteroid therapy for more than 14 days before admission, as
vasculitic changes were shown to diminish between 6 to 14 days
and decrease significantly afterwards22; and (3) nondiagnostic MRI
due to an incomplete protocol and insufficient image quality.
MRI Protocol
All patients were scanned with a 3.0 T scanner (Ingenia; Philips
Healthcare, Best, theNetherlands) using a standard commercial 15-channel
head coil.© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer HThree-dimensional T1-BB-MRI covering the whole brain was
performed before and after application of 0.2 mL/kg body weight of
gadoteric acid (DOTAREM 0.5 mmol/mL; Guerbet, Roissy, France).
The first postcontrast scan was started 5 minutes after injection. De-
tailed scan parameters are listed in Table 1.
Image Analysis
A member of the study group, who did not act as a reader
and was aware of the confirmed clinical diagnosis, selected
the images.
Two radiologists, blinded to the clinical diagnosis with more than
3 years of experience in MRI, independently analyzed the images on a
picture archiving and communication system (Syngo; Siemens AG
Healthcare, Erlangen, Germany). Although the sequence covered the
whole brain, readers were advised to assess the orbital cavity exclu-
sively. Images of patients with andwithout GCAwere provided in a ran-
dom order for both readers. Precontrast and postcontrast images were
reconstructed in all 3 planes with a slice thickness of 1.5 mm. Right
and left orbital cavities were assessed separately.
Image quality and fat suppression of the orbital cavity were rated
as follows: 1, diagnosis strongly impaired; 2, adequate (major artifacts);
3, good (minor artifacts); 4, excellent (no artifacts).
Readers had to assess whether or not arteritic involvement of
the posterior ciliary arteries was present with typical appearance (cir-
cumferential vessel wall thickening and strong contrast enhancement
of the vessel wall20–23) and to assess the diagnostic confidence (DC)
for the presence of vasculitis (1, unlikely; 2, vague; 3, likely; 4, high;
5, very high). A DC of 4 and 5 were considered diagnostic. Further-
more, assessment of visual contrast enhancement (VCE) of the pos-
terior ciliary arteries was rated as follows: 0, none; 1, minimal;
2, moderate; and 3, strong contrast enhancement. Reading was per-
formed separately. A consensus reading was performed in the case
of any differences.www.investigativeradiology.com 699
ealth, Inc. All rights reserved.
FIGURE 1. Flowchart displaying the selection of patients. A-AION,
arteritic anterior ischemic optic neuropathy; GCA, giant cell arteritis;
MRI, magnetic resonance imaging; NA-AION, nonarteritic anterior
ischemic optic neuropathy.
Sommer et al Investigative Radiology • Volume 53, Number 11, November 2018Statistical Analysis
We performed all statistical analyses using SPSS 23 (IBM,
Armonk, NY).
All metric and normally distributed variables are reported as
mean ± standard deviation (SD); nonnormally distributed variables
are presented as median with first-third quartiles (IQR). Ordinal vari-
ables are reported using both median plus IQR and mean ± SD. Cate-
gorical variables are presented as frequency and percentage.
Normal distribution was assessed by the Kolmogorov-Smirnov
test. The χ2 test was used for binomial variables. The t test and Mann-
Whitney U test were used for continuous normally and nonnormally
distributed variables, respectively. Mann-Whitney U test was used for
2 sample comparisons of ordinal variables. Two-sided P values were
determined, and values below 0.05 were considered significant.
Interreader variability of the qualitative parameter “MRI changes”
was assessed by Cohen κ.
RESULTS
Patient Population
A total of 28 patients with visual symptoms suspected for GCA
received MRI. One patient was excluded due to motion artifacts. Eigh-
teen of the 27 patients received the final diagnosis GCA (Fig. 1).TABLE 2. Patient Characteristics
Pat
Age, median (IQR), y
Male sex
Time between systemic steroids (if applied) and MRI, median (IQR), d 4
*Mann-Whitney U test.
†χ2 test.
IQR indicates interquartile range; GCA, giant cell arteritis; MRI, magnetic resonan
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maining nine patients: 3 patients were diagnosed with NA-AION of the
right eye (n = 2) and the left eye (n = 1), 1 with a small subacute throm-
boembolic infarction of the visual cortex, and 5 with nonspecific head-
ache and other causes of visual impairment.
Nine of the 27 patients received TAB in addition to ultrasound to
establish the diagnosis.
Patients with clinically confirmed GCA tended to be older than
patients without GCA, although this difference was not significant
(Table 2). There were no significant differences between the cohorts re-
garding sex and onset time of application of systemic corticosteroids, if
administered (Table 2).
Image Quality of 3D T1-BB-MRI
All images (n = 27) had diagnostic quality with a median of
3 (IQR 3-4; mean ± SD, 3.3 ± 0.8) for the right orbital cavity and a me-
dian of 3 (IQR 2-4; mean ± SD, 3.1 ± 0.8) for the left orbital cavity on a
4-point scale without significant difference regarding right or left side
(U value, 322.5; Z score, 0.718; P = 0.471). Image quality was assessed
to be good to excellent in 77.8% of the cases. Artifacts were seen at the
junction of the maxillary sinus and the orbital cavity, but image quality
was not significantly impaired.
Fat suppression was rated with a median of 4 (IQR 4-4;
mean ± SD, 3.8 ± 0.5) for the right orbital cavity and a median of
4 (IQR 4-4; mean ± SD, 3.8 ± 0.6) for the left orbital cavity on a
4-point scale without significant differences between right and left side
(U value, 362.5; Z score, 0.026; P = 0.976). Local fat suppression was
rated to be good to excellent in 96.3% of the cases.
Findings in Funduscopy
As mentioned previously, 3 patients without GCA were diag-
nosed with atherosclerotic NA-AION. Funduscopy was unremarkable
in the other 6 non-GCA patients.
Fourteen (77.8%) of the 18 patients diagnosed with GCA were
rated positive for A-AION. The latter was detected unilaterally in
8 patients (6 right eyes, 2 left eyes) and bilaterally in 6 patients. Fundus
appearance was unremarkable in the 4 other patients with GCA.
Findings in 3D T1-BB-MRI
None of the patients without GCA displayed contrast enhance-
ment of vessels in the orbital cavity (Fig. 2).
Fourteen of the 18 patients with GCA displayed a strong and
blurry contrast enhancement aside the optic nerve and the adjacent or-
bital fat following the course of the posterior ciliary arteries (Fig. 2). Bi-
lateral enhancement was reported in 13 cases (Fig. 3); unilateral
enhancement of the right side was detected in 1 case.
In the case of contrast enhancement, VCE was rated with a me-
dian of 2 (IQR 2-3; mean ± SD, 2.3 ± 0.7) for the right side and a me-
dian of 3 (IQR 2-3; mean ± SD, 2.4 ± 0.9) for the left side on a 3-point
scale with a DC regarding arteritic involvement with a median of
5 (IQR 4-5; mean ± SD, 4.6 ± 0.5) and a median of 5 (IQR 5-5;
mean ± SD, 4.7 ± 0.6) on a 5-point scale for the right and the left side,ients With GCA (n = 18) Patients Without GCA (n = 9) P
73.8 (69.0–78.0) 65.6 (53.5–77.0) 0.066*
6 (33.3%) 2 (22.2%) 0.881†
.0 (1.8–6.3) (n = 17/18) 6.0 (3.5–7.5) (n = 4/9) 0.745*
ce imaging.
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. The figure displays images of nonenhanced and contrast-enhanced fat suppressed 3D T1-BB-MRI in axial reconstruction of 2 different patients:
patient 1 (upper row) was an 81-year-oldmanwithout GCA according to the diagnostic reference standard and NA-AION of the right eye; MRI did not
show any contrast enhancement of the small vessels adjacent to the optic nerve. Patient 2 (lower row) was a 72-year-old manwith TAB-positive GCA and
bilateral A-AION detected by funduscopy;MRI displayed strong patchy contrast enhancement following the course of the posterior ciliary arteries aside
both optic nerves and the adjacent orbital fat (laterally marked by arrows); high-dose corticosteroid therapy was started 5 days before MRI acquisition.
A-AION, arteritic anterior ischemic optic neuropathy; GCA, giant cell arteritis; NA-AION, nonarteritic anterior ischemic optic neuropathy; TAB, temporal
artery biopsy; MRI, magnetic resonance imaging; 3D T1-BB-MRI, 3-dimensional T1-weighted black-blood magnetic resonance imaging.
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left side regarding VCE (U value, 87.0; Z score, −0.482; P = 0.631) or
DC (U value, 86.5; Z score, −0.505; P = 0.610), respectively.
Findings of 3DT1-BB-MRI ComparedWith Funduscopic
Findings in GCA Patients
Thirteen of the 18 GCA patients displayed both positive findings
in funduscopy regarding A-AION and in MRI regarding arteritic in-
volvement of the posterior ciliary arteries. Three patients did not show
any changes either in funduscopy or inMRI. One patient with unilateral
funduscopic A-AION of the right eye was not detected by MRI. An-
other patient negative for A-AION in funduscopy displayed bilaterally
strong contrast enhancement in MRI indistinguishable to the other
13 patients who were rated positive both by funduscopy and MRI
(Table 3 and Fig. 3, patient 4). When comparing MRI changes and
funduscopy as clinical reference standard in any eye, MRI showed a
sensitivity 92.9% (95% confidence interval [CI], 66.1%–99.8%) and
a specificity of 92.3% (95% CI, 64.0%–99.8%). Positive predictive
value was 92.9% (95% CI, 66.3%–98.9%), and negative predictive
value was 92.3% (95% CI, 64.3%–98.8%).
In general, MRI displayed bilateral involvement in 12 of the 13
cases, whereas funduscopy revealed bilateral A-AION in only 6 of the
13 cases (Fig. 3). Both MRI and funduscopy detected only affection
of the right side in the 1 remaining case.
Reproducibility
There was excellent interreader agreement between both readers
in the assessment of MRI changes (Table 4).
DISCUSSION
This prospective single-center cohort study provides evidence
that high-resolution contrast-enhanced 3D black-blood MRI allows© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer Haccurate diagnosis of ophthalmic involvement in patients with GCA.
Interreader agreement was excellent (κ = 0.852, P < 0.001), implying
that 3D black-blood MRI of the orbital cavity for detection of arteritic
involvement in patients with GCA is reproducible.
Our findings are in line with previous case reports mentioning
contrast enhancement of the optic nerve sheath and the adjacent orbital
fat in patients in with biopsy-proven GCA and corresponding unilat-
eral31 and bilateral A-AION in funduscopy,32–34 respectively.
Moreover, 3D T1-BB-MRI displayed bilateral affection in 12
cases, whereas funduscopy revealed bilateral A-AION in only 6 of these
cases. These findings are also in line with 2 other case reports: both pa-
tients were presenting with unilateral A-AION, but bilateral nodular op-
tic nerve sheath enhancement in MRI. The ESR and c-reactive protein
were normal; however, TAB revealed GCA.35,36 Furthermore, other au-
thors described a case of an 83-year-old woman with rapid progression
of bilateral vision loss, but unremarkable fundus appearance and nor-
mal ESR. The MRI displayed bilateral perineural optic nerve enhance-
ment, and TAB was consistent with GCA.37 The authors stated that
A-PION might have played a role in this patient.
We also encountered 1 patient in our study with bilateral unre-
markable funduscopy, but bilateral contrast enhancement in MRI indis-
tinguishable from the other 13 patients who were rated positive both by
funduscopy and MRI (Fig. 3, patient 4).
Arteritic anterior ischemic optic neuropathy is the morphologic
correlate displayed by funduscopy when ischemia has occurred with
an irreversible impairment of vision. Considering our observations
and the case reports described,MRI seems to depict arteritic ophthalmic
involvement before critic ischemia has developed and might, therefore,
reveal “vision at risk” before being detectable by funduscopy.
Although the other authors described contrast enhancement of the
optic nerve sheath, considering the known pathophysiology of A-AION,
it seems likely that the patchy contrast enhancement adjacent to the
optic nerve displays rather inflammation of the posterior ciliarywww.investigativeradiology.com 701
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FIGURE 3. This figure displays images of axial (A) and coronal (B) reconstructions of contrast-enhanced fat suppressed 3D T1-BB-MRI of 4 different
patients: patient 1: 68-year-old man with GCA and bilateral A-AION as diagnosed by the reference standard; contrast-enhanced MRI displays strong
blurry and patchy enhancement adjacent to the optic nerve bilaterally after the course of the posterior ciliary arteries (arrows), whereas the sheaths of the
optic nerve do not enhance. Susceptibility artifacts can be seen at the junction of the maxillary sinus and the orbit in the coronal reconstruction, but
without overall diagnostic impairment; high-dose corticosteroid therapy was started 14 days beforeMRI acquisition. Patient 2: 52-year-oldmanwith GCA
and A-AION of the right eyewith unremarkable funduscopy of the left eye; however,MRI displayed blurry contrast enhancement of the posterior ciliary
arteries aside the optic nerve of both eyes (arrows) without obvious differences between both sides. The prominent hyperintense superior ophthalmic vein
in both sides visible in the coronal image reconstruction due to ultra-low flow was also notable, however, no other pathologies, such as retinal venous
occlusion, were detected by funduscopy; high-dose corticosteroid therapy was started 1 day before MRI acquisition. Patient 3: 80-year-old woman with
GCA and unilateral A-AION of the left eye detected by funduscopy;MRI again displayed bilateral patchy contrast enhancement aside both optic nerves
(arrows). Artifacts at the junction of the maxillary sinus and the orbit can be seen on both sides, but without significant diagnostic constraints; high-dose
corticosteroid therapy was started 2 days before MRI acquisition. Patient 4: 94-year-old woman with confirmed GCA, but with unremarkable
funduscopy negative for A-AION, but visual disturbances of both eyes; indistinguishable to all other cases shown above, MRI displays strong, patchy
contrast enhancement along the optic nerves and the adjacent orbital fat in the course of the posterior ciliary arteries (arrows); high-dose corticosteroid
therapy was started 2 days before MRI acquisition. A-AION, arteritic anterior ischemic optic neuropathy; GCA, giant cell arteritis; TAB, temporal artery
biopsy; MRI, magnetic resonance imaging; 3D T1-BB-MRI, 3-dimensional T1-weighted black-blood magnetic resonance imaging.
Sommer et al Investigative Radiology • Volume 53, Number 11, November 2018arteries than being correlate of an inflammation of the nerve sheath.
This finding has probably to be attributed to the fact that standard 2D
T1 SE sequences were used without specific blood flow suppres-
sion techniques and with a lower resolution and higher slice702 www.investigativeradiology.com
Copyright © 2018 Wolters Kluwer Hthickness, therefore, lacking the differentiation of anatomic struc-
tures aside the optic nerve. This hypothesis is supported by
Morgenstern et al,34 who found giant cell infiltration of the peri-
neural vasculature in a biopsy of a patient presenting with bilateral© 2018 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
TABLE 4. Interrater Variability Regarding Detection of Vasculitic
Changes of the Posterior Ciliary Arteries in 3D T1-BB-MRI
n Cohen κ P
Vasculitic changes in any eye 27 0.852 <0.001
Vasculitic changes right eye 27 0.852 <0.001
Vasculitic changes left eye 27 0.926 <0.001
3DT1-BB-MRI indicates 3-dimensional T1-weighted black-blood magnetic
resonance imaging.
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over, a breakdown of the blood-optic nerve barrier37 or neovascular-
ization,38 as suggested by other authors, seems unlikely considering
the known pathomechanism of A-AION.
A systematic analysis performed by Geiger et al39 to investi-
gate the diagnostic impact of MRI for the detection of ophthalmic
involvement in patients with GCA could not establish any correla-
tion between funduscopy, visual symptoms, and MRI. The authors
stated that this was probably related to the size of the arteries, as
they could not detect the posterior ciliary arteries with their pro-
posed protocol of 2D SE sequences. Furthermore, arteritic changes
of the ophthalmic artery, as observed in their study, are not causa-
tive for A-AION.
In our study using 3D T1-BB-MRI with a higher spatial reso-
lution and a reconstructed slice thickness of 1.5 mm, the course of
the posterior ciliary arteries aside the optic nerve could be clearly
followed and there were typical signs for vasculitis, such as circum-
ferential wall thickening, strong contrast enhancement, and inflam-
mation of the adjacent soft tissue.20,40
A substantial limitation of our study is the small sample size.
However, GCA is a rare disease and we needed to apply strong inclu-
sion criteria, such as first-time manifestation of GCA and coexis-
tence of A-AION. A prospective multicenter study is necessary to
further substantiate these preliminary findings.
Further, the sequence covered the entire head and readers
had access to all image reconstructions. Although readers were ad-
vised to assess the orbital cavity exclusively, we cannot rule out
that other vessels prone to vasculitic involvement, like the tempo-
ral artery, were also looked at and might have influenced the
decision making.
Moreover, because biopsy of the posterior ciliary arteries in
any patient would not have been justifiable, we can only assume that
MR displays arteritic involvement of the posterior ciliary arteries.
Similarly, there is no clinically applicable criterion standard for diag-
nosing A-PION. As we did not perform a biopsy and A-PION cannot
be proved by funduscopy, we can only hypothesize that bilateral con-
trast enhancement is indicating the contralateral eye at risk. This is
also supported by the fact that we did not detect contrast enhance-
ment in any of the patients without GCA.
Lastly, we did not compare 3D T1-BB-MRI to conventional
2D T1 SE or other sequences.CONCLUSIONS
Our findings demonstrate that 3D T1-BB-MRI allows accurate
diagnosis of arteritic involvement of the posterior ciliary arteries in pa-
tients with GCA and funduscopic A-AION.Moreover, our observations
suggest that MRI can depict ophthalmic involvement much earlier than
funduscopy and might, hence, indicate “vision at risk” before irrevers-
ible vision loss occurs.TABLE 3. Performance of 3D T1-BB-MRI Regarding Detection of
Vasculitic Changes of the Posterior Ciliary Arteries Compared With
Funduscopy Detecting A-AION in Any Eye in All Patients (n = 27)
A-AION Positive A-AION Negative
MRI positive 13/48.2% 1/3.7%
MRI negative 1/3.7% 12/44.4%
χ2 test: P < 0.001.
A-AION indicates arteritic anterior ischemic optic neuropathy;MRI, magnetic
resonance imaging; 3D T1-BB-MRI, 3-dimensional T1-weighted black-blood
magnetic resonance imaging.
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer HTherefore, 3D T1-BB-MRI might provide diagnostic support,
especially in clinically ambiguous cases when vision disturbances due
to GCA are suspected, but patients present with normal inflammatory
blood parameters and unremarkable fundus appearance.REFERENCES
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